Quantitative imaging biomarkers in neuro-oncology

Adam D. Waldman, Alan Jackson, Stephen J. Price, Christopher A. Clark, Thomas C. Booth, Dorothee P. Auer, Paul S. Tofts, David J. Collins, Martin O. Leach, Jeremy H. Rees

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Conventional structural imaging provides limited information on tumor characterization and prognosis. Advances in neurosurgical techniques, radiotherapy planning and novel drug treatments for brain tumors have generated increasing need for reproducible, noninvasive, quantitative imaging biomarkers. This Review considers the role of physiological MRI and PET molecular imaging in understanding metabolic processes associated with tumor growth, blood flow and ultrastructure. We address the utility of various techniques in distinguishing between tumors and non-neoplastic processes, in tumor grading, in defining anatomical relationships between tumor and eloquent brain regions and in determining the biological substrates of treatment response. Much of the evidence is derived from limited case series in individual centers. Despite their 'added value', the effect of these techniques as an adjunct to structural imaging in clinical research and practice remains limited. © 2009 Macmillan Publishers Limited. All rights reserved.
    Original languageEnglish
    Pages (from-to)445-454
    Number of pages9
    JournalNature Reviews Clinical Oncology
    Volume6
    Issue number8
    DOIs
    Publication statusPublished - Aug 2009

    Fingerprint

    Dive into the research topics of 'Quantitative imaging biomarkers in neuro-oncology'. Together they form a unique fingerprint.

    Cite this